PRMT5-IN-29 is a potent and orally active PRMT5 Inhibitor with an IC50 of 1.5 μΜ. PRMT5-IN-29 has the potential for advanced cancers research.
References:
[1]. Liang Lu, et al. Brm targeting compounds and associated methods of use. Patent WO2023287787A1.
















